Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER StudyMartin J. Connor, Verity Watson, Johanna Sukumar et al.|European Urology Oncology|2024Cited by 4
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Carmel Pezaro, Laura Murphy et al.|The Lancet Oncology|2026Cited by 3